Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2023-02-09 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司关于聘任高级管理人员的公告
Board/Management Information Classification · 100% confidence The document is an announcement from 圣湘生物科技股份有限公司 regarding the appointment of a senior management personnel, specifically the hiring of Mr. 殷鹏 as Vice General Manager. It includes details about the board meeting approving the appointment, the term of the appointment, and the resume of the appointed individual. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no mention of shareholder votes or capital changes. The content clearly fits the category of announcing changes in senior management.
2023-02-09 Chinese
圣湘生物科技股份有限公司关于召开2023年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2023 first extraordinary general meeting of shareholders for 圣湘生物科技股份有限公司. It details the meeting date, voting methods, agenda items, and procedural instructions for shareholders. There is no financial data, earnings, or report content included. The document serves as an announcement for the meeting rather than a report or results announcement. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting itself and voting procedures, it aligns best with Proxy Solicitation & Information Statement (PSI). The document length is under 5,000 characters and is a meeting notice, not a report publication announcement or regulatory filing. Hence, the classification is PSI with high confidence.
2023-02-09 Chinese
西部证券股份有限公司关于圣湘生物科技股份有限公司参与投资产业基金暨关联交易事项的核查意见
Regulatory Filings
2023-02-09 Chinese
圣湘生物科技股份有限公司第二届监事会2023年第一次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution passed at the first extraordinary meeting of the second Supervisory Board of the company. It details the meeting date, attendance, agenda, and voting results on a specific investment proposal. There is no financial data, no detailed report, no earnings information, and no mention of a report being attached or published. The content focuses on board-level decision-making and meeting outcomes, which aligns with Board/Management Information filings. The document is short and specific to a board meeting resolution, not a full report or announcement of a report publication.
2023-02-09 Chinese
圣湘生物科技股份有限公司关于参与投资产业基金暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement by 圣湘生物科技股份有限公司 regarding its participation in an investment fund and related party transactions. It includes information about the investment fund, the investment amount, the nature of the transaction as a related party transaction, approvals by the board and supervisory committee, independent directors' opinions, risk disclosures, and compliance with regulatory requirements. The document does not contain financial statements or quarterly results but is a formal disclosure of a capital investment and related party transaction. This fits the category of Capital/Financing Update (CAP), as it updates on the company's financing activities and capital structure changes through investment in an industry fund. The document length and detail confirm it is not a brief announcement or a simple regulatory filing, but a substantive update on financing activity.
2023-02-09 Chinese
圣湘生物科技股份有限公司独立董事关于第二届董事会2023年第二次临时会议相关事宜的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing their prior approval opinion on a specific board meeting agenda item regarding an investment and related party transaction. It references the board meeting date and the agenda but does not contain financial statements or detailed financial data. The document is short (490 characters) and is essentially a governance-related announcement about board approval and opinions. This fits best under Board/Management Information (MANG), which covers announcements related to board or senior management matters.
2023-02-09 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.